Drug Repurposing and Screening for Multiple Sclerosis Targeting Microglia and Macrophages
Molecular Neurobiology · 2025
DOI: 10.1007/s12035-024-04602-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Neurobiology, 2025. Verfasst von Nandi Bao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Cardiology, the Sixth Medical Center of PLA General Hospital, Beijing, 100048, China. Hauptthemen laut MEDLINE: Microglia, Drug Repositioning, Multiple Sclerosis, Macrophages. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Chinese PLA General Hospital, Beijing Nova Program Grant.
Abstract (Originalsprache)
Microglia/macrophages (MG/Mφ) play a central role in the pathogenesis of multiple sclerosis (MS). However, the intricacies of the immunomodulatory microenvironment in MS, particularly the heterogeneity and regulatory mechanisms of MG/Mφ subpopulations, remain elusive. The commonly used treatment options for MS have several drawbacks, such as significant side effects and uncertain efficacy. The exploration of developing new drugs targeting MG/Mφ for the treatment of MS remains to be investigated. We identified three distinct subpopulations of MG/Mφ, among which MG/Mφ_3 significantly increased as the experimental autoimmune encephalomyelitis (EAE) progressed. Ifenprodil and RO-25-6981 demonstrated notable inhibition of inflammatory factor expression, accompanied by reduced cytotoxicity. The interaction modes of these compounds with the common binding pocket in the GluN1b-GluN2B amino terminal domain heterodimer were elucidated. Virtual docking, based on the N-methyl-D-aspartate (NMDA) receptor, showed that homo-skeleton compounds of ifenprodil potentially exhibit low binding free energy with the receptor, including eliprodil and volinanserin. In vitro cell models corroborated the effective inhibition of inflammatory factor expression and minimal cytotoxicity of eliprodil and volinanserin. CoMFA (standard error of estimate = 0.378, R2 = 0.928, F values = 241.255, Prob. of R2 = 0) and topomer CoMFA (q2 = 0.553, q2 stderr = 0.77, intercept = - 1.48, r2 = 0.908, r2 stderr = 0.35) were established based on the inhibitors of NMDA receptor. The contour maps of CoMFA and topomer CoMFA models give structural information to improve the inhibitory function. This study underscores the involvement of MG/Mφ in inflammatory pathways during MS progression and offers promising compound candidates for MS therapy targeting MG/Mφ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Cardiology, the Sixth Medical Center of PLA General Hospital, Beijing, 100048, China.
- Institute of Geriatrics, National Clinical Research Center of Geriatrics Disease, the Second Medical Center of PLA General Hospital, Beijing, 100853, China.
- Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
- National Supercomputing Shenzhen Center, Shenzhen, 518052, China.
- Institute of Geriatrics, National Clinical Research Center of Geriatrics Disease, the Second Medical Center of PLA General Hospital, Beijing, 100853, China. jiajianjun301@126.com.
- Medical Supplies Center of PLA General Hospital, Beijing, 100853, China. zmreformer@126.com.
Förderung
- Chinese PLA General Hospital
- Beijing Nova Program Grant
Zitieren
APA
Bao, N., Liu, J., Wang, H., Xing, L., Xie, Z., Liu, C., Jin, S., Jia, J., Zhang, M., & Fan, J. (2025). Drug Repurposing and Screening for Multiple Sclerosis Targeting Microglia and Macrophages. Molecular Neurobiology. https://doi.org/10.1007/s12035-024-04602-w
Vancouver
Bao N, Liu J, Wang H, Xing L, Xie Z, Liu C, et al. Drug Repurposing and Screening for Multiple Sclerosis Targeting Microglia and Macrophages. Molecular Neurobiology. 2025. doi:10.1007/s12035-024-04602-w
BibTeX
@article{Bao2025,
author = {Bao, Nandi and Liu, Jing and Wang, Heran and Xing, Lei and Xie, Zhonghui and Liu, Chuanbin and Jin, Shaowei and Jia, Jianjun and Zhang, Minghua and Fan, Jiao},
title = {Drug Repurposing and Screening for Multiple Sclerosis Targeting Microglia and Macrophages},
journal = {Molecular Neurobiology},
year = {2025},
doi = {10.1007/s12035-024-04602-w}
}
EUVIMED